X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA PFIZER ELDER PHARMA/
PFIZER
 
P/E (TTM) x -0.2 34.2 - View Chart
P/BV x 0.1 4.8 2.1% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ELDER PHARMA   PFIZER
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
PFIZER
Mar-18
ELDER PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs3802,365 16.1%   
Low Rs1881,625 11.6%   
Sales per share (Unadj.) Rs491.2430.3 114.2%  
Earnings per share (Unadj.) Rs-3.278.7 -4.0%  
Cash flow per share (Unadj.) Rs14.493.2 15.5%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs376.5586.5 64.2%  
Shares outstanding (eoy) m20.5445.75 44.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.64.6 12.5%   
Avg P/E ratio x-89.325.3 -352.1%  
P/CF ratio (eoy) x19.721.4 92.1%  
Price / Book Value ratio x0.83.4 22.2%  
Dividend payout %025.4 0.0%   
Avg Mkt Cap Rs m5,83391,271 6.4%   
No. of employees `000NA2.6 0.0%   
Total wages/salary Rs m2,1793,143 69.3%   
Avg. sales/employee Rs ThNM7,484.8-  
Avg. wages/employee Rs ThNM1,195.0-  
Avg. net profit/employee Rs ThNM1,369.1-  
INCOME DATA
Net Sales Rs m10,08919,685 51.3%  
Other income Rs m2571,143 22.5%   
Total revenues Rs m10,34620,828 49.7%   
Gross profit Rs m-7925,003 -15.8%  
Depreciation Rs m361663 54.5%   
Interest Rs m2,7564 65,626.2%   
Profit before tax Rs m-3,6535,479 -66.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1251,878 6.7%   
Profit after tax Rs m-653,601 -1.8%  
Gross profit margin %-7.825.4 -30.9%  
Effective tax rate %-3.434.3 -10.0%   
Net profit margin %-0.618.3 -3.5%  
BALANCE SHEET DATA
Current assets Rs m9,24024,167 38.2%   
Current liabilities Rs m9,9989,544 104.7%   
Net working cap to sales %-7.574.3 -10.1%  
Current ratio x0.92.5 36.5%  
Inventory Days Days4655 84.1%  
Debtors Days Days6029 208.8%  
Net fixed assets Rs m10,1249,514 106.4%   
Share capital Rs m206458 45.0%   
"Free" reserves Rs m5,58226,375 21.2%   
Net worth Rs m7,73426,832 28.8%   
Long term debt Rs m4,88925 19,556.0%   
Total assets Rs m22,88236,900 62.0%  
Interest coverage x-0.31,305.5 -0.0%   
Debt to equity ratio x0.60 67,851.1%  
Sales to assets ratio x0.40.5 82.6%   
Return on assets %11.89.8 120.4%  
Return on equity %-0.813.4 -6.3%  
Return on capital %22.320.4 109.3%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30722 1,368.8%   
Fx outflow Rs m1251,489 8.4%   
Net fx Rs m181-1,466 -12.4%   
CASH FLOW
From Operations Rs m11,7543,318 354.3%  
From Investments Rs m-561-2,383 23.5%  
From Financial Activity Rs m-6,762-1,104 612.8%  
Net Cashflow Rs m4,432-169 -2,630.1%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 7.5 7.5 100.0%  
FIIs % 16.8 4.9 342.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 23.7 152.3%  
Shareholders   16,479 85,207 19.3%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   AJANTA PHARMA  FDC LTD.  SUN PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Yes Bank & Tata Motors Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note. Sectoral indices are trading on a positive note with stocks in the realty sector.

Related Views on News

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - FRESENIUS KABI ONCO. COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS